Biopharmaceuticals in European hospitals
Number | 4114 |
---|---|
Project manager | Steinar Strøm |
Client | Norges forskningsråd |
Client project no. | |
Participants | Ugo Colombino Marilena Locatelli |
Period | 2010 - 2012 (ended) |
Project description
In this project we analyze how prices and funding schemes affect the medical doctors use of different types of biopharmaceuticals in the treatment of arthritis. There are three drugs available in the European markets: Enbrel, Remicade and Humira. Data covers the last 10 years and 10 European countries, including the Nordic countries.Publications
Scientific Journal
Author(s): | Title: | Year: | Reference: | Link: |
---|---|---|---|---|
Dalen, Dag Morten, Marilena Locatelli, Enrico Sorisio, Steinar Strøm | Does the Identity of the Third-Party Payer Matter for Prescribing Doctors? | 2014 | Applied Economics and Finance vol 1(1), 39-54 | [PDF] |
Brekke, K.R., D.M. Dalen og S. Strøm | Should pharmaceutical costs be curbed? | 2012 | Nordic Economic Policy Review 2, 1-27 | [PDF] |
Other publications
Author(s): | Title: | Year: | Reference: | Link: |
---|---|---|---|---|
Dalen, Dag Morten, Enrico Sorisio and Steinar Strøm | Choosing among Competing Blockbusters: Does the Identity of the Third-Party Payer Matter for Prescribing Doctors? | 2010 | CESifo Working paper no. 3227 | [PDF] |
Dalen, Dag Morten, Marilena Locatelli and Steinar Strøm | Longitudinal Analysis of Generic Substitution | 2010 | CESifo Working paper no. 3176 | [PDF] |